# Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10

> **NCT00992212** · PHASE2 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 418 (actual)

## Conditions studied

- Pandemic Influenza Disease

## Interventions

- **BIOLOGICAL:** Monovalent A/H1N1 influenza vaccine

## Key facts

- **NCT ID:** NCT00992212
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2009-10
- **Final completion:** 2009-11
- **Target enrollment:** 418 (ACTUAL)
- **Last updated:** 2016-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00992212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00992212, "Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00992212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*